.jpeg)
2026-04-09 05:34:17
Provides a comprehensive interpretation of the findings from the POLAR phase II basket trial, published in Nature Medicine in March 2026. It details the efficacy, biomarker analysis, and clinical value of olaparib (a PARP inhibitor) combined with pembrolizumab (an anti-PD-1 immunotherapy) as biomarker-guided maintenance therapy for patients with metastatic pancreatic cancer who achieved disease control after platinum-based chemotherapy, offering cutting-edge clinical reference for the precision treatment of pancreatic cancer.
2026-04-01 02:16:12
Cancer cells act as "rebellious agents" disrupting bodily harmony. Through global research advancements, we uncover the mechanisms of cancer formation, differences in types, and innovative therapies. From surgical removal to immunotherapy, scientific progress offers new hope. Dive into the mysteries of cancer and its future treatment prospects.
2026-03-25 01:39:36
IRX4 as a transcription factor shows downregulated expression in colorectal cancer. Research reveals it can inhibit cancer cell proliferation and enhance chemotherapy sensitivity. This article analyzes IRX4 mechanisms and clinical application potential.
2026-03-20 03:27:09
Clonal hematopoiesis of indeterminate potential refers to somatic mutations in hematopoietic stem cells, associated with tumor development, with standardized research holding important value for precision medicine.
2026-03-18 06:00:53
Latest systematic review study finds that use of tyrosine kinase inhibitors and Janus kinase inhibitors may be associated with increased keratinocyte carcinoma risk, providing important reference for tumor drug therapy safety assessment.
2026-03-18 05:49:30
CLISGen is an innovative database platform integrating SNP genotype information from cancer cell lines, containing genetic data from over 1000 cancer cell lines, helping researchers efficiently select cell models with specific genetic variations and breaking through bottlenecks in tumor functional genomics research.
2026-03-12 07:35:33
RAS mutations account for approximately 30% of malignancies, but resistance limits clinical benefits. New research reveals sustained mTORC1 activity as a non-genetic driver of RAS inhibitor resistance. Farnesyltransferase inhibitor Dalifarnib (KO-2806) blocks mTORC1 activation via RHEB, achieving rapid durable tumor regression when combined with RAS inhibitors.
2026-03-12 07:23:51
ARID1A is a key subunit of the SWI/SNF chromatin remodeling complex, with mutations linked to various cancers. Recent research reveals ARID1A deficiency triggers viral mimicry, enhancing tumor immunogenicity and providing new immunotherapy targets.
2026-02-01 22:25:32
